IVD Industry Strengthens Expansion, Indonesia Targeted as Southeast Asian Manufacturing Base
The in vitro diagnostics (IVD) industry is changing its business strategy amid slowing government spending on medical devices and global economic uncertainty. Industry players are now strengthening penetration into the private market while expanding exports to sustain business growth.
Associate Commercial Director of PT Virtue Diagnostics Indonesia Kurniasari Endah said the strategic shift is a response to changing market dynamics over recent years.
“We recognise that entering the Indonesian market in 2024 was not an easy journey. Besides facing challenging market conditions, we also had to build trust in local IVD products amid the dominance of global brands that have been present for decades,” Kurniasari said at the Industrial Symposium at INDOHEALTHCARE GAKESLAB Expo 2026 in Jakarta on Thursday (6/8/2026).
According to her, the company is now strengthening penetration into hospitals, clinical laboratories, and private healthcare facilities as a new source of growth amid declining government spending on medical devices.
The strategy is beginning to show results. By mid-2026, Virtue Diagnostics Indonesia has produced more than 150 diagnostic instruments and 31,000 reagent kits used in various hospitals and laboratories across Indonesia. The company has also obtained ISO 13485 certification for its medical device quality management system and has begun exporting VIRTUEDX-branded reagents and VERCENTRA diagnostic instruments to the Philippines.
Founder and Global CEO of Virtue Diagnostics Johnson Zhang said the company is also continuing to strengthen manufacturing in Indonesia as a production base to meet both domestic and export market needs.
“Indonesia has great potential to become an IVD manufacturing hub in Southeast Asia. To realise this, synergy between the government and industry is needed through policies that support long-term investment,” Johnson said.
Virtue Diagnostics currently operates a 12,200 square metre manufacturing facility in Cikarang with a production capacity of more than 1,000 diagnostic instruments per year and 6,000 litres of reagent per day. The company has also obtained marketing authorisation for 193 diagnostic products in Indonesia. A number of these products have a domestic component level (TKDN) above 40 percent.
Going forward, the company plans to increase investment in research and development, expand production capacity, and strengthen distribution networks in domestic and international markets.
Source: jawawa.id (https://jawawa.id/newsitem/ivd-industry-strengthens-expansion-indonesia-targeted-as-southeast-asian-manufacturing-base-1786103634)
Originally published by Republika (https://ekonomi.republika.co.id/berita/tjecht416/industri-ivd-perkuat-ekspansi-indonesia-dibidik-jadi-basis-manufaktur-asia-tenggara), translated from Indonesian